Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Jun;27(6):851–859. doi: 10.1111/j.1365-2125.1989.tb03449.x

Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.

M H Devenport 1, D Crook 1, V Wynn 1, L J Lees 1
PMCID: PMC1379814  PMID: 2547410

Abstract

1. Azole antifungal agents such as ketoconazole act by inhibiting cytochrome P-450 mediated sterol synthesis in the fungal cell membrane and thus have the potential to interfere with mammalian steroidogenesis. Fluconazole is a novel orally-effective antifungal triazole which has been reported to have more specific effects on the cytochrome P-450 enzymes involved in fungal sterol synthesis. 2. Due to the potential value of systemic antifungal agents in the treatment of infections commonly occurring in women, we assessed the effect of oral fluconazole on the metabolic profile of 18 healthy premenopausal women, 10 of whom were taking combined oral contraceptives (OC). Each woman acted as her own control, being studied both before and 21-28 days after fluconazole therapy (50 mg daily), in the luteal phase of consecutive menstrual cycles. 3. The endocrinological profile included measurement of serum oestradiol, progesterone, testosterone and sex hormone binding globulin (SHBG) concentrations, short tetracosactrin adrenal stimulation test and thyroid function tests. Carbohydrate metabolism was investigated by means of an oral glucose tolerance test with measurement of plasma glucose, insulin and C-peptide concentrations. Serum lipids, lipoproteins and apolipoproteins were analysed on samples taken after an overnight fast. 4. Minor biochemical changes associated with fluconazole treatment included increases in serum thyroxine and testosterone concentrations (but not in women taking OC as well as fluconazole) and in insulin and apolipoprotein B levels (but only in women taking OC as well as fluconazole). In general, these changes were small and of no clinical significance with the values remaining within the laboratory normal range. There were no adverse side-effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
858

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albano J. D., Ekins R. P., Maritz G., Turner R. C. A sensitive, precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinol (Copenh) 1972 Jul;70(3):487–509. doi: 10.1530/acta.0.0700487. [DOI] [PubMed] [Google Scholar]
  2. D'Mello A. P., D'Souza M. J., Bates T. R. Pharmacokinetics of ketoconazole-antipyrine interaction. Lancet. 1985 Jul 27;2(8448):209–210. doi: 10.1016/s0140-6736(85)91517-x. [DOI] [PubMed] [Google Scholar]
  3. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed] [Google Scholar]
  4. Gidez L. I., Miller G. J., Burstein M., Slagle S., Eder H. A. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982 Nov;23(8):1206–1223. [PubMed] [Google Scholar]
  5. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Iqbal M. J., Johnson M. W. Study of steroid-protein binding by a novel "two-tier" column employing Cibacron Blue F3G-A-Sepharose 4B. I-Sex hormone binding globulin. J Steroid Biochem. 1977 Sep;8(9):977–983. doi: 10.1016/0022-4731(77)90196-0. [DOI] [PubMed] [Google Scholar]
  7. Kraemer F. B., Pont A. Inhibition of cholesterol synthesis by ketoconazole. Am J Med. 1986 Apr;80(4):616–622. doi: 10.1016/0002-9343(86)90816-8. [DOI] [PubMed] [Google Scholar]
  8. Laurell C. B. Electroimmuno assay. Scand J Clin Lab Invest Suppl. 1972;124:21–37. doi: 10.3109/00365517209102748. [DOI] [PubMed] [Google Scholar]
  9. Lewis J. H., Zimmerman H. J., Benson G. D., Ishak K. G. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. 1984 Mar;86(3):503–513. [PubMed] [Google Scholar]
  10. Mason J. I., Murry B. A., Olcott M., Sheets J. J. Imidazole antimycotics: inhibitors of steroid aromatase. Biochem Pharmacol. 1985 Apr 1;34(7):1087–1092. doi: 10.1016/0006-2952(85)90613-6. [DOI] [PubMed] [Google Scholar]
  11. Miettinen T. A. Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res. 1988 Jan;29(1):43–51. [PubMed] [Google Scholar]
  12. Pont A., Graybill J. R., Craven P. C., Galgiani J. N., Dismukes W. E., Reitz R. E., Stevens D. A. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1984 Nov;144(11):2150–2153. [PubMed] [Google Scholar]
  13. Pont A., Williams P. L., Azhar S., Reitz R. E., Bochra C., Smith E. R., Stevens D. A. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982 Nov;142(12):2137–2140. [PubMed] [Google Scholar]
  14. Ratcliffe W. A., Challand G. S., Ratcliffe J. G. A critical evaluation of separation methods in radiommunoassay for total triiodothyronine and thyroxine in unextracted human serum. Ann Clin Biochem. 1974 Nov;11(6):224–229. doi: 10.1177/000456327401100166. [DOI] [PubMed] [Google Scholar]
  15. Santen R. J., Van den Bossche H., Symoens J., Brugmans J., DeCoster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab. 1983 Oct;57(4):732–736. doi: 10.1210/jcem-57-4-732. [DOI] [PubMed] [Google Scholar]
  16. Sonino N., Boscaro M., Merola G., Mantero F. Prolonged treatment of Cushing's disease by ketoconazole. J Clin Endocrinol Metab. 1985 Oct;61(4):718–722. doi: 10.1210/jcem-61-4-718. [DOI] [PubMed] [Google Scholar]
  17. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987 Sep 24;317(13):812–818. doi: 10.1056/NEJM198709243171307. [DOI] [PubMed] [Google Scholar]
  18. Trachtenberg J., Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet. 1984 Aug 25;2(8400):433–435. doi: 10.1016/s0140-6736(84)92909-x. [DOI] [PubMed] [Google Scholar]
  19. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969 Mar;22(2):158–161. doi: 10.1136/jcp.22.2.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Warnick G. R., Albers J. J. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 1978 Jan;19(1):65–76. [PubMed] [Google Scholar]
  21. Watanabe H., Menzies J. A. Depression of ovarian estradiol-17 beta following single oral dose of ketoconazole. Res Commun Chem Pathol Pharmacol. 1985 Apr;48(1):141–144. [PubMed] [Google Scholar]
  22. Wild R. A., Umstot E. S., Andersen R. N., Givens J. R. Adrenal function in hirsutism. II. Effect of an oral contraceptive. J Clin Endocrinol Metab. 1982 Apr;54(4):676–681. doi: 10.1210/jcem-54-4-676. [DOI] [PubMed] [Google Scholar]
  23. Wynn V., Doar J. W. Some effects of oral contraceptives on carbohydrate metabolism. Lancet. 1966 Oct 1;2(7466):715–719. doi: 10.1016/s0140-6736(66)92978-3. [DOI] [PubMed] [Google Scholar]
  24. Wynn V., Godsland I. Effects of oral contraceptives on carbohydrate metabolism. J Reprod Med. 1986 Sep;31(9 Suppl):892–897. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES